Ustekinumab
- CAS No.
- 815610-63-0
- Chemical Name:
- Ustekinumab
- Synonyms
- Ustekinuma;ustekinumab;Ustekinumab USP/EP/BP;Research Grade Ustekinumab;Research Grade Ustekinumab(DHD84001);inhibit,Interleukin Related,Inhibitor,Ustekinumab
- CBNumber:
- CB61518546
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| storage temp. | Store at -80°C |
|---|---|
| solubility | Soluble in DMSO |
| form | Liquid |
| color | Colorless to light yellow |
| FDA UNII | FU77B4U5Z0 |
| NCI Drug Dictionary | ustekinumab |
| ATC code | L04AC05 |
Ustekinumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Biosynth | BU165596 | Ustekinumab | 815610-63-0 | 1mg | $1947 | 2026-06-04 | Buy |
| Biosynth | BU165596 | Ustekinumab | 815610-63-0 | 5mg | $3407.25 | 2026-06-04 | Buy |
| Biosynth | BU165596 | Ustekinumab | 815610-63-0 | 10mg | $4429.5 | 2026-06-04 | Buy |
| ChemScene | CS-7823 | Ustekinumab 99.83% | 815610-63-0 | 1mg | $596 | 2026-06-04 | Buy |
| ChemScene | CS-7823 | Ustekinumab 99.83% | 815610-63-0 | 5mg | $1051 | 2026-06-04 | Buy |
Ustekinumab Chemical Properties,Uses,Production
Description
Psoriasis is a chronic inflammatory skin disorder that affects approximately 2-3% of the world’s population. The most common form of the
disease is plaque psoriasis, which is a result of dysregulated cell growth.
Conventional treatment options for psoriasis include topical corticosteroids, phototherapy, and systemic drugs (oral retinoids, cyclosporine, and
MTX), but all of these therapies have limitations.
Ustekinumab
is the latest biologic to be approved for the treatment of plaque psoriasis.
It is a human IgG1k monoclonal antibody that binds with high affinity and specificity to the p40 protein subunit used by both the interleukin-12
(IL-12) and interleukin-23 (IL-23) cytokines. IL-12 and IL-23 are naturally
occurring cytokines that are involved in inflammatory and immune
responses, such as NK cell activation and CD4+ T-cell differentiation
and activation. In in vitro models, ustekinumab is shown to disrupt IL12- and IL-23-mediated signaling and cytokine cascades by disrupting the
interaction of these cytokines with a shared cell-surface receptor chain,
IL-121. Ustekinumab is indicated for the treatment of adult patients (18
years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
Adverse events associated with the use of ustekinumab included nasopharyngitis, upper respiratory tract infection, headache, fatigue, and diarrhea.
Originator
Medarex (US)
Uses
Ustekinumab is used to treat plaque psoriasis, a certain type of arthritis or certain bowel conditions.
brand name
Stelara
IC 50
IL-12; IL-23
Ustekinumab Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai Boyle Chemical Co., Ltd. | sales@boylechem.com | China | 2915 | 55 | |
| Wuhan Sunrise Technology Development Co., Ltd. | 27-027-83314682 13554138826 | whsrtech@vip.163.com | China | 140 | 62 |
| Shanghai Fuhe Chemistry Technology Co., Ltd. | 0086-21-67651709 | cfx759@hotmail.com | China | 409 | 57 |
| Wuhan Fortuna Chemical Co., Ltd | 027-59207852 13308628970 | buy@fortunachem.com | China | 2698 | 58 |
| Dalian Meilun Biotech Co., Ltd. | 0411-62910999 13889544652 | sales@meilune.com | China | 4765 | 58 |
| Nanjing Sunlida Biological Technology Co., Ltd. | 025-57798810 18652991625 | sales@sunlidabio.com | China | 3223 | 55 |
| Sichuan Wei Keqi Biological Technology Co., Ltd. | 028-81700200 18116577057 | 3003855609@qq.com | China | 7717 | 56 |
| Shanghai Macklin Biochemical Co.,Ltd. | 15221275939 15221275939 | shenlinxing@macklin.cn | China | 15775 | 55 |
| Taizhou KEDE Chemical Co., Ltd | 0576-84613060 13093829633;13736603231; | sales@kedechemical.com | China | 299 | 60 |
| Shanghai Lollane Biological Technology Co.,Ltd. | 021-52996696，15000506266 15000506266 | China | 4860 | 55 |
View Lastest Price from Ustekinumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-08-20 | Ustekinumab USP/EP/BP
815610-63-0
|
$1.10 | 1g | 99.9% | 100 Tons Min | Dideu Industries Group Limited | |
 |
2026-07-27 | Ustekinumab
815610-63-0
|
$455.00-1280.00 | 98.00% | 10g | TargetMol Chemicals Inc. | ||
 |
2020-05-03 | Ustekinumab
815610-63-0
|
1KG | 99.0% | 800 ton | Shaanxi Dideu Medichem Co. Ltd |
-
- Ustekinumab USP/EP/BP
815610-63-0
- $1.10
- 99.9%
- Dideu Industries Group Limited
-
- Ustekinumab
815610-63-0
- $455.00-1280.00
- 98.00%
- TargetMol Chemicals Inc.
-
- Ustekinumab
815610-63-0
- 99.0%
- Shaanxi Dideu Medichem Co. Ltd
